MEREO BIOPHARMA GROUP PL-ADR (MREO)

Company Profile

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The company is focused on the development of therapeutics for rare diseases. The company has developed a portfolio of clinical-stage product candidates. The firm has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). The company also has two oncology product candidates in clinical development. The company also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Company Info

MEREO BIOPHARMA GROUP PL-ADR

One Cavendish Place, Fourth Floor

London W1G0QF

P: 4403330237300

CEO: Denise Scots-Knight

Employees: 36

Website: https://www.mereobiopharma.com/